vadimezan has been researched along with lapatinib in 1 studies
Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) |
---|---|---|---|---|---|
272 | 16 | 101 | 1,919 | 305 | 1,442 |
Protein | Taxonomy | vadimezan (IC50) | lapatinib (IC50) |
---|---|---|---|
Bile salt export pump | Homo sapiens (human) | 7.375 | |
Epidermal growth factor receptor | Homo sapiens (human) | 0.0827 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0537 | |
Platelet-derived growth factor receptor beta | Homo sapiens (human) | 8.5 | |
D(1A) dopamine receptor | Sus scrofa (pig) | 0.06 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1 | |
Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1659 | |
Alpha-1A adrenergic receptor | Sus scrofa (pig) | 0.06 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ye, G; Zhang, C; Zhang, J | 1 |
1 other study(ies) available for vadimezan and lapatinib
Article | Year |
---|---|
Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Interferons; Lapatinib; Male; Membrane Proteins; Mice, Inbred BALB C; Nucleotides, Cyclic; Pyridines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Vascular Endothelial Growth Factor Receptor-2; Xanthones; Xenograft Model Antitumor Assays | 2021 |